Financial Analysis: LifePoint Health (LPNT) and American Renal Associates Holdings (ARA)
LifePoint Health (NASDAQ: LPNT) and American Renal Associates Holdings (NYSE:ARA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.
Institutional and Insider Ownership
99.5% of LifePoint Health shares are held by institutional investors. Comparatively, 89.9% of American Renal Associates Holdings shares are held by institutional investors. 7.3% of LifePoint Health shares are held by insiders. Comparatively, 12.6% of American Renal Associates Holdings shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares LifePoint Health and American Renal Associates Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|American Renal Associates Holdings||-1.54%||18.25%||2.62%|
This is a summary of current ratings and price targets for LifePoint Health and American Renal Associates Holdings, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|American Renal Associates Holdings||1||0||3||0||2.50|
LifePoint Health presently has a consensus target price of $65.50, suggesting a potential upside of 16.65%. American Renal Associates Holdings has a consensus target price of $23.50, suggesting a potential upside of 66.20%. Given American Renal Associates Holdings’ stronger consensus rating and higher possible upside, analysts clearly believe American Renal Associates Holdings is more favorable than LifePoint Health.
Earnings & Valuation
This table compares LifePoint Health and American Renal Associates Holdings’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|LifePoint Health||$6.42 billion||0.35||$760.40 million||$4.48||12.53|
|American Renal Associates Holdings||$755.09 million||0.59||$150.25 million||($0.23)||-61.48|
LifePoint Health has higher revenue and earnings than American Renal Associates Holdings. American Renal Associates Holdings is trading at a lower price-to-earnings ratio than LifePoint Health, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
LifePoint Health has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, American Renal Associates Holdings has a beta of 3.77, meaning that its share price is 277% more volatile than the S&P 500.
American Renal Associates Holdings beats LifePoint Health on 7 of the 13 factors compared between the two stocks.
About LifePoint Health
LifePoint Health, Inc., through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers and post-acute facilities. As of December 31, 2016, the Company operated 72 hospital campuses in 22 states, having a total of 9,424 licensed beds. It offers a range of general and specialized healthcare services to patients through a network of hospitals and outpatient facilities. Its services include general surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, rehabilitation services and pediatric services, and in some of its hospitals, the Company offers specialized services, such as open-heart surgery, skilled nursing, psychiatric care and neuro-surgery. It provides outpatient services, such as same-day surgery, laboratory, x-ray, respiratory therapy, imaging, sports medicine and lithotripsy.
About American Renal Associates Holdings
American Renal Associates Holdings, Inc. is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia. The Company operates its dialysis clinics exclusively through a JV model, in which it partners primarily with local nephrologists to develop, own and operate dialysis clinics, while the providers of the majority of dialysis services in the United States operate through a combination of subsidiaries and joint ventures. It provides patient care and clinical outcomes to patients suffering from end-stage renal disease (ESRD). Its clinics offer both in center and home dialysis options to meet the needs of patients. Its clinics primarily provide in center hemodialysis treatments and ancillary items and services.
Receive News & Stock Ratings for LifePoint Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifePoint Health Inc. and related stocks with our FREE daily email newsletter.